Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Answer questions and earn CME/CNE

[1]  R. Hellweg,et al.  Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology and Biochemistr and Biochemistr and Biochemistr and Biochemistr and Biochemistryyyyy Phosphatidylinositide Dependent Kinase Deficiency Increases Anxiety and Decreases GABA and Serotonin Abundance in t , 2022 .

[2]  I. Pedrosa,et al.  Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. , 2012, European journal of cancer.

[3]  A. Hauschild,et al.  Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[5]  Gary H Lyman,et al.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Wolbring,et al.  Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.

[7]  B. Barlogie,et al.  Bradycardia during therapy for multiple myeloma with thalidomide. , 2004, The American journal of cardiology.

[8]  H. Kato,et al.  Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. , 2008, American journal of respiratory and critical care medicine.

[9]  D. Fruman,et al.  S6 kinase 2 potentiates interleukin‐3‐driven cell proliferation , 2005, Journal of leukocyte biology.

[10]  S. Rane,et al.  Hematopoietic cytokine receptor signaling , 2007, Oncogene.

[11]  P. Hammerman,et al.  Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. , 2005, Blood.

[12]  A. Ravaud,et al.  Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Maroto,et al.  Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Valent,et al.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML , 2011, American journal of hematology.

[15]  H. Kong,et al.  Lack of Association Between Excretion of Sorafenib in Sweat and Hand‐Foot Skin Reaction , 2010, Pharmacotherapy.

[16]  A. Laties,et al.  Preconditioning with Bright Light Evokes a Protective Response against Light Damage in the Rat Retina , 1998, The Journal of Neuroscience.

[17]  P. Casali,et al.  A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  J. Harding,et al.  Vemurafenib sensitivity skin reaction after ipilimumab. , 2012, The New England journal of medicine.

[19]  Sabine Tejpar,et al.  Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. , 2007, The Journal of clinical investigation.

[20]  P. Sonneveld,et al.  General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. , 2012, Seminars in hematology.

[21]  S. Tejpar,et al.  Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling. , 2010, Journal of the American Society of Nephrology : JASN.

[22]  J. Schellens,et al.  Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[23]  B. Thiers.  Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study , 2009 .

[24]  B. Cho,et al.  Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy , 2011, International journal of hematology.

[25]  G. Morgan,et al.  A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. , 2012, Blood.

[26]  E. Price,et al.  MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes , 1998, Nature.

[27]  L. S. Harrington,et al.  Restraining PI3K: mTOR signalling goes back to the membrane. , 2005, Trends in biochemical sciences.

[28]  P. Gean,et al.  Regulation of Amygdala-Dependent Learning by Brain-Derived Neurotrophic Factor is Mediated by Extracellular Signal-Regulated Kinase and Phosphatidylinositol-3-Kinase , 2006, Neuropsychopharmacology.

[29]  H. Lane,et al.  Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. , 2004, Bone.

[30]  R. Paus,et al.  Sonic hedgehog signaling is essential for hair development , 1998, Current Biology.

[31]  T. Choueiri,et al.  Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Wen,et al.  Neurological adverse effects caused by cytotoxic and targeted therapies , 2009, Nature Reviews Clinical Oncology.

[33]  J. Strausz,et al.  Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). , 2010 .

[34]  S. Sleijfer,et al.  Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. , 2011, The Journal of clinical endocrinology and metabolism.

[35]  Michele Cavo,et al.  Proteasome inhibitors in multiple myeloma: 10 years later. , 2012, Blood.

[36]  James X. Song,et al.  Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Matthew J. Oborski,et al.  Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts. , 2012 .

[38]  H. Lodish,et al.  Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. , 2006, Blood.

[39]  E. Van Cutsem,et al.  Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. , 2007, The Lancet. Oncology.

[40]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[41]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[42]  J. Ware,et al.  A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Giaccone,et al.  Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia , 2012, Clinical Cancer Research.

[44]  A. Malafosse,et al.  Alterations in Phosphatidylinositol 3-Kinase Activity and PTEN Phosphatase in the Prefrontal Cortex of Depressed Suicide Victims , 2011, Neuropsychobiology.

[45]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[46]  J. McCubrey,et al.  The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. , 2010, Biochimica et biophysica acta.

[47]  J. Soria,et al.  Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Halpern,et al.  A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. , 2009, Journal of the American Academy of Dermatology.

[49]  F. Rojo,et al.  First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors , 2012, Clinical Cancer Research.

[50]  M. Alter,et al.  The hand‐foot‐syndrome associated with medical tumor therapy – classification and management , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[51]  J. Schellens,et al.  Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. , 2011, Journal of analytical toxicology.

[52]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[53]  K. Matsumoto,et al.  Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. , 2000, The Journal of clinical investigation.

[54]  R. Duman,et al.  A Role for MAP Kinase Signaling in Behavioral Models of Depression and Antidepressant Treatment , 2007, Biological Psychiatry.

[55]  Tiffany Shao,et al.  The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Dimopoulos,et al.  How to manage neutropenia in multiple myeloma. , 2012, Clinical lymphoma, myeloma & leukemia.

[57]  M. Zhu,et al.  Meta‐analysis: The efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer , 2009, Journal of digestive diseases.

[58]  Michael A. Davies,et al.  Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[59]  A. Zambelli,et al.  Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. , 2011, Breast.

[60]  B. Hasinoff,et al.  The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. , 2010, Toxicology and applied pharmacology.

[61]  M. Milella,et al.  Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials , 2008, Breast Cancer Research and Treatment.

[62]  Hans Clevers,et al.  Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells , 2005, Nature.

[63]  E. Raymond,et al.  First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. , 2010 .

[64]  R. Vij,et al.  The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects , 2013, Leukemia.

[65]  U. Costabel,et al.  Bronchoalveolar lavage in drug-induced lung disease. , 2004, Clinics in chest medicine.

[66]  M. Ychou,et al.  Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm , 2012, Supportive Care in Cancer.

[67]  F. Lang,et al.  Rapamycin-induced phosphaturia. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[68]  J. Cornish,et al.  Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell‐Dependent Mechanisms , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[69]  R. DePinho,et al.  Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis , 2010, The EMBO journal.

[70]  M. Chen,et al.  Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase , 2009, Clinical and translational science.

[71]  D. Sawyer,et al.  Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern? , 2010, Circulation research.

[72]  Yu-hong Wang,et al.  Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. , 2008, Journal of the American Academy of Dermatology.

[73]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[74]  Yong Huang,et al.  Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data , 2010, J. Biomed. Informatics.

[75]  M. Ratain,et al.  Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. , 2011, British journal of clinical pharmacology.

[76]  D. Schadendorf,et al.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  M. Humbert,et al.  Résultats tardifs de la commissurotomie mitrale percutanée à 20 ans Création et validation d ’ un score de risque prédisant les résultats fonctionnels à long terme à partir d ’ une série de 912 patients , 2012 .

[78]  C. Lacombe,et al.  Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. , 2003, Blood.

[79]  J. Ware,et al.  A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  R. Doebele,et al.  Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer , 2012, Cancer.

[81]  A. Halpern,et al.  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  E. Perez,et al.  Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. , 2008, Mayo Clinic proceedings.

[83]  M. Ko,et al.  PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. , 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[84]  C. Chevreau,et al.  Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? , 2009, Targeted Oncology.

[85]  M. Boccadoro,et al.  Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. , 2012, Blood.

[86]  J. Blay,et al.  Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors , 2012, Medical Oncology.

[87]  D. Leroith,et al.  Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia , 2011, Oncogene.

[88]  H. Kong,et al.  Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. , 2009, Archives of dermatology.

[89]  D. Moro-Sibilot,et al.  Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[90]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[91]  C. Berking,et al.  Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. , 2012 .

[92]  S. Misbah,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[93]  J. Harney,et al.  Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior , 2010, Physiology & Behavior.

[94]  I. Durán,et al.  Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma , 2010, Anti-cancer drugs.

[95]  S. Pang,et al.  Hand‐foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy , 2007, The British journal of dermatology.

[96]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[97]  G. Bepler,et al.  Cancer Cachexia: Traditional Therapies and Novel Molecular Mechanism-Based Approaches to Treatment , 2010, Current treatment options in oncology.

[98]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[100]  J. Gustafsson,et al.  Rexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[101]  M. Detmar,et al.  Control of hair growth and follicle size by VEGF-mediated angiogenesis. , 2001, The Journal of clinical investigation.

[102]  K. Flaherty,et al.  Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. , 2012 .

[103]  D. Kaplan,et al.  The TrkB-Shc Site Signals Neuronal Survival and Local Axon Growth via MEK and PI3-Kinase , 2000, Neuron.

[104]  D. Sargent,et al.  Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 , 2008, Oncology.

[105]  L. Seymour,et al.  Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[106]  Weida Tong,et al.  In silico drug repositioning: what we need to know. , 2013, Drug discovery today.

[107]  G. Cohen,et al.  BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. , 2011, Blood.

[108]  Helen X. Chen,et al.  Adverse effects of anticancer agents that target the VEGF pathway , 2009, Nature Reviews Clinical Oncology.

[109]  P. Pah.  Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: Who's afraid of the big bad wolf? , 2012 .

[110]  M. Lacouture,et al.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  Susumu Minamisawa,et al.  ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.

[112]  G J M Parker,et al.  Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Y. Yarden,et al.  Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells , 2007, Proceedings of the National Academy of Sciences.

[114]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[115]  M. Lacouture,et al.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities , 2011, Supportive Care in Cancer.

[116]  G. Gamble,et al.  Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. , 2009, The Journal of clinical endocrinology and metabolism.

[117]  G. Imokawa,et al.  Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF‐M , 2004, The Journal of pathology.

[118]  A. Tefferi,et al.  Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. , 2011, Mayo Clinic proceedings.

[119]  Shenhong Wu,et al.  Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. , 2011, JAMA.

[120]  K. Kuwano,et al.  EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. , 2011, American journal of respiratory and critical care medicine.

[121]  Roger T. Anderson,et al.  Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life , 2010, Cancer.

[122]  F. Efficace,et al.  Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf? , 2012, Leukemia research.

[123]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[124]  P. Larsen,et al.  Thyroid dysfunction from antineoplastic agents. , 2011, Journal of the National Cancer Institute.

[125]  H. Xin,et al.  Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation , 2008, Cancer science.

[126]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[127]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[128]  N. Senzer,et al.  A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[129]  R. Maki,et al.  Pigmentary changes in a patient treated with imatinib. , 2011, Journal of drugs in dermatology : JDD.

[130]  L. Rosen,et al.  Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib , 2012, Cancer.

[131]  Patricia M. LoRusso,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers , 2010, Clinical Cancer Research.

[132]  H. Mackay,et al.  Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis , 2012, Clinical Cancer Research.

[133]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[134]  C. Sternberg,et al.  Targeted therapies for renal cell carcinoma: review of adverse event management strategies. , 2012, Journal of the National Cancer Institute.

[135]  S. Barni,et al.  Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[136]  Andreas Hochhaus,et al.  Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  J. Baselga,et al.  Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[138]  C. Gentili,et al.  Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway , 2006, Journal of neurochemistry.

[139]  M. Ychou,et al.  Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. , 2012, The oncologist.

[140]  R. Mesa,et al.  A phase-2 trial of low-dose pomalidomide in myelofibrosis , 2011, Leukemia.

[141]  D. Esseltine,et al.  Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. , 2005, Blood.

[142]  J. Valentin,et al.  Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspective , 2008, British journal of pharmacology.

[143]  D. V. Von Hoff,et al.  Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  P. Cony-Makhoul,et al.  Imatinib mesylate and gray hair. , 2002, The New England journal of medicine.

[145]  Robert Beckman,et al.  Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  T. Choueiri,et al.  Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2009, The Lancet. Oncology.

[147]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[148]  K. Sugihara,et al.  A Japanese Post-marketing Surveillance of Cetuximab (Erbitux®) in Patients with Metastatic Colorectal Cancer , 2012, Japanese journal of clinical oncology.

[149]  Stephen W Dusza,et al.  Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. , 2006, Journal of the American Academy of Dermatology.

[150]  Janosch Achenbach,et al.  Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. , 2012, Biochemical pharmacology.

[151]  Estelle Marrer,et al.  Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. , 2010, Leukemia research.

[152]  Yusu Gu,et al.  A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[153]  L. French,et al.  Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders , 2010, Clinical Cancer Research.

[154]  T. Muchamuel,et al.  Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events , 2011, Clinical Cancer Research.

[155]  Marjolein Visser,et al.  Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. , 2003, The Journal of clinical endocrinology and metabolism.

[156]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[157]  F. Goldwasser,et al.  Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[158]  Sunita Ghosh,et al.  Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma , 2012, British Journal of Cancer.

[159]  L. Dogliotti,et al.  Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[160]  A. Ullrich,et al.  Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. , 1995, The EMBO journal.

[161]  J. Singer,et al.  UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia , 2007, Leukemia.

[162]  J. Köhrle,et al.  Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. , 2012, The Journal of clinical endocrinology and metabolism.

[163]  G. Shapiro,et al.  AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. , 2010 .

[164]  R. Dummer,et al.  Minimizing adverse side‐effects of oral bexarotene in cutaneous T‐cell lymphoma: an expert opinion , 2006, The British journal of dermatology.

[165]  C. Sima,et al.  Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design , 2011, Clinical Cancer Research.

[166]  G. Shapiro,et al.  Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. , 2011 .

[167]  G. Szot,et al.  Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice , 2008, Proceedings of the National Academy of Sciences.

[168]  Santhosh K. P. Kumar,et al.  Thalidomide as initial therapy for early-stage myeloma , 2003, Leukemia.

[169]  J. Berlin,et al.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  P. Marik,et al.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies. , 2008, Canadian respiratory journal.

[171]  A. Croft,et al.  Second to none , 1996 .

[172]  Joanne L. Jones,et al.  Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis , 2012, Expert review of neurotherapeutics.

[173]  M. Konopleva,et al.  Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. , 2008, Journal of the National Cancer Institute.

[174]  R. Motzer,et al.  Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma , 2012, Cancer.

[175]  M. Boccadoro,et al.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. , 2010, Blood.

[176]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[177]  T. Yue,et al.  Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. , 2000, Circulation research.

[178]  S. Lonial,et al.  Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes , 2011, Leukemia.

[179]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[180]  J. Hoenderop,et al.  EGF increases TRPM6 activity and surface expression. , 2009, Journal of the American Society of Nephrology : JASN.

[181]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  T. Brümmendorf,et al.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. , 2012, Blood.

[183]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[184]  J. Cherrington,et al.  Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans , 2003, Journal of Pharmacology and Experimental Therapeutics.

[185]  S. Fitter,et al.  NVP‐BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[186]  D. Nochy,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[187]  P. Contu,et al.  Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. , 2010, The oncologist.

[188]  J. Lademann,et al.  The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. , 2009, Anticancer research.

[189]  Jeffrey W. Clark,et al.  Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  B. Jessen,et al.  Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[191]  C. Gambacorti-Passerini,et al.  Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib , 2008, Haematologica.

[192]  Rui Zhang,et al.  Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials , 2011, European Journal of Clinical Pharmacology.

[193]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[194]  A. McCullough.  RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .

[195]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  R. Fleischmajer,et al.  Tetracyclines: nonantibiotic properties and their clinical implications. , 2006, Journal of the American Academy of Dermatology.

[197]  G. Giaccone,et al.  Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. , 2010, European journal of cancer.

[198]  B. Dörken,et al.  Severe peripheral arterial disease during nilotinib therapy. , 2011, Journal of the National Cancer Institute.

[199]  J. Carver,et al.  Myocarditis During Lenalidomide Therapy , 2010, The Annals of pharmacotherapy.

[200]  Juxiang Chen,et al.  Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. , 2011, Cancer treatment reviews.

[201]  L. Birdsell,et al.  Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  M. Loriot,et al.  Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study , 2012, PloS one.

[203]  Chun-Fang Xu,et al.  Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism , 2010, British Journal of Cancer.

[204]  L. Siu,et al.  Molecularly targeted oncology therapeutics and prolongation of the QT interval. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[205]  Helen X. Chen,et al.  Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[206]  P. Svenningsson,et al.  Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration , 2011, Molecular Psychiatry.

[207]  H. Guchelaar,et al.  Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  A. Unami,et al.  Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia. , 2008, Biological & pharmaceutical bulletin.

[209]  Shuyan Lu,et al.  Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[210]  M. Lacouture,et al.  Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[211]  H. Kong,et al.  Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[212]  J. Romijn,et al.  Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. , 2007, The Journal of clinical endocrinology and metabolism.

[213]  B. Barlogie,et al.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.

[214]  M. Boccadoro,et al.  Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[215]  H. Kantarjian,et al.  The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase , 2004, Cancer.

[216]  K. J. Henley,et al.  Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. , 2011, Blood.

[217]  Ming-Chih Crouthamel,et al.  Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors , 2009, British Journal of Cancer.

[218]  J. Li,et al.  Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. , 2010, Cardiovascular research.

[219]  K. Kalantar-Zadeh,et al.  Management of mineral and bone disorder after kidney transplantation , 2012, Current opinion in nephrology and hypertension.

[220]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[221]  J. Romijn,et al.  Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. , 2010, The Journal of clinical endocrinology and metabolism.

[222]  T. Meyer,et al.  Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice , 2009, Journal of thrombosis and haemostasis : JTH.

[223]  H. Kantarjian,et al.  Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure , 2009, Cancer.

[224]  S. Wulf,et al.  Amendment history : Corrigendum ( November 2013 ) An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic , 2018 .

[225]  J. Lademann,et al.  Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[226]  A. Unami,et al.  Mechanisms of HDAC inhibitor-induced thrombocytopenia. , 2007, European journal of pharmacology.

[227]  Lei Wu,et al.  Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. , 2004, Cellular immunology.

[228]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[229]  A. Rademaker,et al.  Higher severity grade of erlotinib‐induced rash is associated with lower skin phototype , 2011, Clinical and experimental dermatology.

[230]  D. Alexandrescu,et al.  Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. , 2008, Dermatology online journal.

[231]  B. Hasinoff,et al.  Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib , 2010, Cardiovascular Toxicology.

[232]  P. Schöffski,et al.  Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors , 2009, Acta oncologica.

[233]  D. V. van Spronsen,et al.  The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases , 2009, Acta oncologica.

[234]  B. Hasinoff.  The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. , 2010, Toxicology and applied pharmacology.

[235]  R. Motzer,et al.  Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.